Provided by Tiger Trade Technology Pte. Ltd.

Eledon Pharmaceuticals, Inc.

2.98
-0.2200-6.88%
Post-market: 3.030.0500+1.68%19:52 EDT
Volume:1.84M
Turnover:5.53M
Market Cap:242.16M
PE:-3.02
High:3.18
Open:3.18
Low:2.93
Close:3.20
52wk High:4.60
52wk Low:1.35
Shares:81.26M
Float Shares:74.57M
Volume Ratio:1.87
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9867
EPS(LYR):-0.5566
ROE:-110.71%
ROA:-39.02%
PB:3.36
PE(LYR):-5.35

Loading ...

Eledon Pharmaceuticals files $500M mixed securities shelf

TIPRANKS
·
May 02

Newcelx Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026

THOMSON REUTERS
·
Apr 30

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

Benzinga Earnings
·
Apr 30

Eledon Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 21

NewcelX publishes updated corporate presentation

Reuters
·
Apr 20

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
Mar 24

Eledon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 20

Corrected-Eledon Pharmaceuticals: FY (Not 'Q4') EPS $-0.52

THOMSON REUTERS
·
Mar 20

Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs

Reuters
·
Mar 20

Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate

Benzinga Earnings
·
Mar 20

Eledon Pharmaceuticals FY Operating Expenses USD 83.251 Million

THOMSON REUTERS
·
Mar 20

Press Release: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Dow Jones
·
Mar 20

Eledon Pharmaceuticals: Q4 EPS $-0.52

THOMSON REUTERS
·
Mar 20

Eledon FY 2025 net loss was USD 45.6 million as R&D expenses rose 27.5% to USD 66.3 million

Reuters
·
Mar 20

Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings

TIPRANKS
·
Mar 20

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 18

Sernova Biotherapeutics publishes MD&A for the three months ended Jan. 31, 2026 and 2025

Reuters
·
Mar 16

Eledon announces updated data from islet transplant trial of tegoprubart

TIPRANKS
·
Mar 16

Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Mar 16

Eledon reports 100% insulin independence in 10 patients in tegoprubart islet transplant trial

Reuters
·
Mar 16